Sana Biotechnology SC451 (hypoimmune stem-cell islets)
Sana Biotechnology
A cure without anti-rejection drugs — unproven.
What it is
SC451 is a stem-cell-derived hypoimmune islet candidate with no human testing identified in the checked sources, designed to work without anti-rejection drugs. Human findings from the related donor-islet product UP421 provide platform context, not evidence that SC451 itself is effective or safe.
Editorial review: .
Most recent recorded citation date: 2026-08-10. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Preclinical evidence. Benefit in people has not been established.See the linked studies and their populations →
- Benefit or performance
- Efficacy: SC451 has no human efficacy reported in the checked sources. The UP421 donor-islet case uses a different product and cannot establish SC451 insulin independence.[5]
- Important harms and treatment burden
- Safety: No SC451-specific clinical safety testing was identified in the checked sources. Donor-islet UP421 tolerability cannot establish risks of the stem-cell-derived product.[5]
- Approval and country access
- SC451 is not an available treatment. The company is preparing for clinical development; ages and regions from the UP421 study are not SC451 eligibility.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: No human SC451 graft-durability result was identified in the checked sources; UP421 follow-up is separate platform evidence.[5]
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. This speculative assessment includes intended performance or preclinical findings; it does not establish benefit in people.
Default calculation: 15 × 20 + 10 × 12 + 20 × 16 + 40 × 20 + 20 × 12 + 12 × 20 = 2020; divide by total weight 100. Unrounded weighted result: 20.2.
SC451 has no human efficacy reported in the checked sources. The UP421 donor-islet case uses a different product and cannot establish SC451 insulin independence.[5]
No human SC451 graft-durability result was identified in the checked sources; UP421 follow-up is separate platform evidence.[5]
No SC451-specific clinical safety testing was identified in the checked sources. Donor-islet UP421 tolerability cannot establish risks of the stem-cell-derived product.[5]
Avoiding immunosuppression is the SC451 design goal, not a demonstrated human outcome for this candidate in the checked sources.[5]
No registered SC451 eligibility was established in the checked sources. UP421 ages are not an SC451 label.[5]
The August company update describes preparation for IND submission and a Phase 1/2 start. The candidate remains preclinical.[5]
Immunosuppression-free is scored here, as it is for cell replacement and encapsulation — freeing a therapy from lifelong anti-rejection drugs is the central barrier this whole pillar is trying to clear, so an approach that achieves it must be able to earn credit for it. It is scored on evidence, not intent: a platform designed to avoid immunosuppression but never yet tested at a therapeutic dose scores on what it has shown. Approaches that transplant nothing (in-vivo gene therapy, reprogramming) need no anti-rejection drugs by construction, but they still face the original autoimmune attack — that unresolved risk belongs in this score, not hidden by it.
The full picture
Candidate and development plan
SC451 is Sana’s O-negative, hypoimmune-modified, induced-pluripotent-stem-cell-derived islet candidate. Restoring glucose control without insulin or immunosuppressive drugs is its goal, not a demonstrated SC451 outcome in the checked sources. Scores and the evidence badge describe SC451; related UP421 findings provide context.5
The August company update described toxicology, manufacturing transfer and trial preparation. September SEC-filed slides retained a 2026 IND and phase 1/2 start goal. These are development plans, not proof of clearance or enrollment. An exact-name ClinicalTrials.gov search on 17 September returned no SC451 records; that limited search does not exclude every other registry or study name.576
Related human evidence: a different product
UP421 uses gene-edited primary donor islets. Its original report describes transplantation into one man’s forearm without immunosuppressive drugs. At 12 weeks, C-peptide was stable and glucose responsive, with no detected immune response against the fully hypoimmune-modified cells. Four adverse events occurred; none was serious or attributed to the islet-cell product. Lower-arm paresthesia was possibly procedure-related.8
The UP421 registry planned two participants. That target is not the published study denominator. The old recruiting label, last updated in December 2024, does not guarantee current availability.4
A NEJM letter published online 10 July 2026 reports longer follow-up. Its abstract supports function and lack of detected immune response through 14 months, but the full outcome tables were not accessible here. Sana’s July announcement describes continued insulin secretion and no identified safety issues. The detailed follow-up remains attributed to the company account.12
This low-dose study was not designed to demonstrate insulin independence. It does not establish SC451’s safety, effective dose, durability or eligibility, and does not show that immune protection will persist indefinitely.2 See the SC451 development record for source and protocol limits.
Coming soon
ETA · The August company update and September presentation retain a 2026 IND and Phase 1/2 start goal. An exact-name ClinicalTrials.gov search on 17 September returned no records; no availability date is established.
- →File Investigational New Drug (IND) application for SC451 · as early as 2026
- →Begin first Phase 1/2 trial of SC451 (iPSC-derived hypoimmune islets) · as early as 2026
Sources
- [1]Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression (Letter) · Peer-reviewed study · 2026-07-10 — Carlsson PO, Hu X, Scholz H, et al. N Engl J Med 2026. PMID 42430558. A Letter to the Editor, not a full paper — 14-month follow-up of the single UP421 recipient. Full letter text was not independently accessible in this refresh; detailed follow-up below is attributed to the company’s report.
Carlsson P-O, et al. Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression. NEJM, online 10 July 2026.
- [2]Sana Biotechnology Announces Follow-On Publication in the New England Journal of Medicine Highlighting Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes · Manufacturer · 2026-07-13 — Company release announcing the NEJM Letter; also states Sana expects to file an IND and start a Phase 1/2 trial of SC451 "as early as this year".
Sana Biotechnology. Announcement of NEJM follow-up, 13 July 2026.
- [3]Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression · Peer-reviewed study · 2025-08-04 — Carlsson PO, et al. N Engl J Med 2025. The original first-in-human UP421 report (12-week data).
- [4]First-in-Human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes (UP421) · Trial registry · 2024-02-02 — NCT06239636 is the separate UP421 donor-islet study. It does not establish SC451 enrolment or availability.
ClinicalTrials.gov. NCT06239636, checked 17 September 2026.
- [5]Sana Q2 2026 update — SC451 preparation for IND submission and Phase 1/2 · Manufacturer · 2026-08-10 — SC451 development plans and identity; no SC451 human outcomes.
Sana Biotechnology. Second-quarter update, 10 August 2026.
- [6]ClinicalTrials.gov exact-name search for SC451 — no records returned on 17 September 2026 · Trial registry — A negative name search does not exclude a differently named or non-US registration.
ClinicalTrials.gov. Exact-name SC451 search, checked 17 September 2026.
- [7]Sana September 2026 corporate presentation filed with the SEC · Manufacturer — Slides 3 and 13–16 describe development goals and readiness; not IND clearance, enrollment or outcomes.
Sana Biotechnology. September 2026 corporate presentation, slides 3 and 13–16.
- [8]
Carlsson P-O, et al. Original UP421 12-week report, 2025. https://doi.org/10.1056/NEJMoa2503822